Finally, we demonstrated positive correlations between PRMT2 and WNT5A expression and poor clinicopathological characteristics, and poor survival in RCC patients, indicating that targeting PRMT2 is a potential therapeutic strategy in RCC patients, especially for metastatic RCC patients. This evidence concerns the gene PRMT2 and renal cell carcinoma.